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MaWe present a case of acute myocarditis with left ventricular dysfunction and intracavitary thrombosis in a 55-year-old
man with severe acute respiratory syndrome coronavirus 2 infection (coronavirus disease 2019) who was admitted with
bilateral atypical pneumonia. The patient was treated with anticoagulation and optimal heart failure therapy and had an
improvement of left ventricular function and thrombus resolution. (Level of Difficulty: Intermediate.) (J Am Coll Cardiol
Case Rep 2021;-:-–-) © 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology
Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).A 55-year-old man who tested positive for se-vere acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) (the agent of
coronavirus disease-2019 [COVID-19]) was admitted
to the intensive care unit of Vall d’Hebron University
Hospital, Barcelona, with a diagnosis of bilateral
atypical pneumonia (Figure 1). Blood tests demon-
strated leukopenia, elevated C-reactive protein of
12.35 mg/dl, and interleukin-6 levels of 1,946 pg/dl.
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were unremarkable. Blood pressure was 144/
77 mm Hg, heart rate was 84 beats/min, body temper-
ature was 36C, and respiration rate was 24 breaths/
min. The patient required high- flow oxygen through
a nasal cannula (fraction of inspired oxygen [FiO2] 1)
to maintain a peripheral oxygen saturation of 96%.
However, 3 days after hospitalization, D-dimer levels
increased significantly (up to 12,835 ng/ml), as did
troponin I and NT-proBNP levels (4,162 ng/l and
7,460 pg/ml, respectively). He had no cardiovascular
symptoms and was hemodynamically stable. A
bedside echocardiogram showed a dilated left
ventricle withmoderate systolic dysfunction (left ven-
tricular [LV] ejection fraction [LVEF] of 35% to 40%),
global hypokinesia, and a huge multilobed, mobile,
and hyperechogenic mass measuring 41  26 mmhttps://doi.org/10.1016/j.jaccas.2021.01.030
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FIGURE 1 Chest Radiograph on Admission
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FiO2 = fraction of inspired
oxygen
LV = left ventricular
LVEF = left ventricular ejection
fraction
NT-proBNP = N-terminal pro–
B-type natriuretic peptide
SARS-CoV-2 = severe acute
respiratory syndrome-
coronavirus-2
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and attached to the apex. Right ventricular
function was preserved (tricuspid annular
plane systolic excursion of 22 mm and tis-
sue Doppler systolic wave [S] of 12 cm/s),
and there was no valve disease (Figures 2A
and 2B, Videos 1 and 2). With these
findings, anticoagulation with full-dose
low-molecular-weight heparin and heart
failure treatment (carvedilol and enalapril)
were started.
PAST MEDICAL HISTORY
His past medical history included obesity
(body mass index, 31 kg/m2) and obstructive
sleep apnea syndrome requiring continuouspositive airway pressure. He had no previous cardio-
vascular disease.
DIFFERENTIAL DIAGNOSIS
Given the patient’s clinical presentation with LV
dysfunction, the differential diagnosis included
ischemic cardiomyopathy, myocarditis, and decom-
pensation of a previously unknown cardiomyopathy.
Because of the presence of a huge intraventricular
mass, thrombus versus intracardiac tumor was
proposed.
INVESTIGATIONS
An electrocardiogram showed a previously unknown
left bundle branch block (Figure 3). At 6 and 7 days
after the echocardiogram and the start of anti-
coagulation, cardiac computed tomography and car-
diac magnetic resonance (CMR) were performed.
Computed tomography showed no coronary lesions
and a dilated left ventricle with moderate systolic
dysfunction (LVEF, 38%) (Figures 4A to 4D). No
intracavitary mass was visualized. CMR revealed
mildly increased diffuse wall thickness with an
elevated myocardial signal intensity in the anterior
middle and apical wall in balanced steady-state free
precession cine sequences. In addition, short tau
inversion recovery images showed mild hyper-
intensity of the anterior wall, with a T2 ratio of
myocardium to skeletal muscle of 2.6. Native T1
mapping was elevated overall (native T1 of 1,107 ms
[reference values 950 to 1,050 ms]), as was the
extracellular volume ( 29%). T2 mapping sequences
showed an elevated global T2 value of 62 ms (65 ms in
the anterior and anteroseptal wall, 55 ms in the
inferior wall). Late gadolinium enhancement se-
quences demonstrated no foci or areas of contrast
uptake; nevertheless, there was a diffuse mildhyperintensity of the middle and apical anterior wall
(slow contrast washout). Overall, these findings are
suggestive of diffuse myocardial edema, predomi-
nantly in the anterior wall (Figures 5, 6A to 6C, and 7,
Videos 3 and 4). First-pass perfusion and early and
late gadolinium enhancement were performed, and
no intraventricular mass was observed, a finding that
suggested a thrombotic origin. Because 2 comple-
mentary studies had demonstrated the absence of a
mass, a second echocardiogram during hospitaliza-
tion was not performed to reduce the risk of conta-
gion for the sonographer, according to international
recommendations (1). The patient did not experience
any symptoms or signs suggestive of peripheral
embolism.
MANAGEMENT
The patient required only high-flow oxygen (FiO2 1)
with no requirements of ventilation or hemodynamic
support. He was treated with ceftriaxone, azi-
thromycin, hydroxychloroquine, lopinavir and rito-
navir in combination, and tocilizumab, according to
the local protocol at the time. Anticoagulation with
full-dose low-molecular-weight heparin was also
prescribed, as well as complete heart failure therapy.
DISCUSSION
Severe acute respiratory syndrome associated with
SARS-CoV-2 infection appears to affect the myocar-
dium by different mechanisms (2): infection-related
myocarditis, hypoxemia, and/or ischemia, and it is
considered an important prognostic factor (3). More-
over, COVID-19 may be associated with a hypercoag-
ulable state. There is evidence of a high prevalence of
clinically relevant thrombosis, essentially pulmonary
FIGURE 2 Bedside 2-Dimensional Echocardiography
The images show a dilated left ventricle with a huge multilobed, mobile, and hyperechogenic mass attached to the apex (arrows). Left
ventricle in (A) the apical 4 chamber view and (B) the apical 3-chamber view.
FIGURE 3 Electrocardiogram on Admission
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FIGURE 4 Coronary Computed Tomography Angiography
The images show no coronary stenosis in (A) the right coronary artery, (B) the left anterior descending artery, and (C) the circumflex artery. (D) No evidence of left
ventricular thrombus is noted.
FIGURE 5 Balanced Steady-State Free Precession Cine
Images in the 2-Chamber View
Mildly increased wall thickness and higher myocardial signal
intensity in the anterior middle and apical wall (arrowheads).
Servato et al. J A C C : C A S E R E P O R T S , V O L . - , N O . - , 2 0 2 1
Intraventricular Conundrum in a SARS-CoV-2 Patient - 2 0 2 1 :- –-
4
embolisms (16.7%), in patients with hypoxemic acute
respiratory failure (4). Furthermore, venous and
arterial thromboembolisms are emerging as among
the most severe sequelae of the disease associated
with poorer outcomes (5). In addition, acute coronary
syndromes are noted to occur after severe acute res-
piratory syndrome (6).
We report a case of myocarditis associated with
COVID-19 with LV dysfunction and a large mobile LV
thrombus in a young patient with no cardiovascular
history. This thrombus could have resulted in severe
complications without prompt diagnosis and treat-
ment initiation. Because endomyocardial biopsy is
not recommended in patients with COVID-19 and
suspected myocarditis (1), and given that the patient
had a good evolution, a biopsy was not performed.
Moreover, recent biopsy data revealed that T1 and T2
increase in this population is related to myocarditis
(lymphocytic infiltrates) (7).
Although the presence of elevated troponin I is
frequently seen in patients with myocarditis and is
usually associated with myocyte necrosis, our pa-
tient had elevated troponin but no late gadolinium
enhancement. We believe that these findings can be
explained by the marked myocardial inflammation
and associated submillimetric and nonhomogeneous
areas of necrosis (8). The lesser severity of myocardial
injury also explains the overall improvement of
myocardial systolic function during follow-up,whereas the expansion of the extracellular space is
supported by the finding of increased native T1 and
T2 mapping, as well as increased extracellular
volume.
Echocardiography is helpful in assessing cardiac
hemodynamics in the presence of chest pain, elec-
trocardiographic changes, or biomarker elevation
FIGURE 6 Short Tau Inversion Recovery and Mapping Images
(A) Short tau inversion recovery images in the short axis with mild hyperintensity of the anterior wall (arrowheads). (B) T1 mapping study shows an overall elevated
native T1 value of 1,107 ms and an extracellular volume of 29%. (C) T2 mapping shows an elevated global T2 value of 62 ms (65 ms in the anterior and anteroseptal
wall, 55 ms in the inferior wall).
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suggestive of myocardial injury, myopericarditis, or
fulminant myocarditis (9), and it should be planned
in patients with new onset of malignant ventricular
arrhythmias not associated with a prolonged QT in-
terval (10). As demonstrated in our case, echocardi-
ography permitted accurate diagnosis and
management.
We highlight the importance of echocardiography
in patients with SARS-CoV-2 infection and elevatedFIGURE 7 Late Gadolinium Enhancement Images
Late gadolinium enhancement images in the 2-chamber (left) and mid–s
Nevertheless, there is diffuse mild hyperintensity of the middle and apiheart injury biomarkers, to establish a correct diag-
nosis, guide management, and reduce complications.
To the best of our knowledge, no similar case has
been published.
FOLLOW-UP
The patient was discharged in good clinical condi-
tion. He is currently receiving the followinghort-axis views (right) with no evidence of focal necrosis or fibrosis.
cal anterior wall (arrows).
FIGURE 8 Control Echocardiogram 2 Months After Discharge Showing Left Ventricular Function Improvement and the Absence of
Intraventricular Thrombus
Left ventricle in (A) the apical 4-chamber view and (B) the apical 3-chamber view.
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medications: carvedilol, 6.25 mg b.i.d.; enalapril, 5
mg o.d.; and acenocoumarol. Two months after
discharge, he is asymptomatic, and an echocardio-
gram revealed improvements in contractility and
ventricular function (LVEF, 50%), as well as the
absence of intracavitary thrombus (Figures 8A and 8B,
Videos 5 and 6). Moreover, control CMR showed aFIGURE 9 Control Cardiac Magnetic Resonance
The images show normalization of (A) T1 and (B) T2 values.normalization of T1 and T2 values (Figures 9A and 9B,
Videos 7 and 8).
CONCLUSIONS
This is a rare case of myocarditis with acute LV
thrombosis and dysfunction in a young patient with
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SARS-CoV-2 pneumonia. The patient had a favorable
clinical evolution under anticoagulation and heart
failure treatment. We highlight the importance of
echocardiography in patients with SARS-CoV-2
infection and biomarker elevation suggestive of
myocardial injury, to guide management and reduce
complications and mortality.
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